United Therapeutics develops treatments for pulmonary arterial hypertension and related serious diseases. Its prostacyclin-based franchise includes different formulations and delivery systems for treprostinil, while its research includes organ manufacturing and transplantation-related technologies. The company generates product sales from specialty prescriptions and reinvests in pulmonary and regenerative medicine programs.
United Therapeutics Corp. (UTHR) has a MarketKingdoms composite score of 62.7 (B-), an B-range rating. It ranks 1066th of 1,866 covered companies, 52nd of 78 in Healthcare (sector average 64.4) and 4th of 6 in Drug Manufacturers - Specialty & Generic. Scores as of 2026-10-26.
Its strongest lenses are Quality (profitability) at 83 (Healthcare average 50) and Industry opportunity at 74 (Healthcare average 81). Its weakest lenses are Expansion (growth) at 44 (sector average 50) and Price (valuation) at 47 (sector average 50).
| Lens | Type | UTHR | Healthcare average | Drug Manufacturers - Specialty & Generic average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 74 | 81 | 74 | 15th |
| Stock selection | Research signal | 66 | 79 | 76 | 6th |
| KPI momentum | Research signal | 72 | 78 | 71 | 31st |
| Catalyst watch | Research signal | 54 | 74 | 71 | 4th |
| Price (valuation) | Fundamental lens | 47 | 50 | 65 | 41st |
| Expansion (growth) | Fundamental lens | 44 | 50 | 39 | 44th |
| Quality (profitability) | Fundamental lens | 83 | 50 | 63 | 96th |
| Trend (momentum) | Fundamental lens | 51 | 50 | 48 | 49th |
The most recent call analysed was held on 2026-08-05 (fiscal 2026 Q2). MarketKingdoms checks what management promised on each call against what it later delivered.
The stock's valuation gap is -10.5%: its price is below the path its market, sector and industry moves explain (undervalued versus the model path). Factor sensitivity: market beta -0.49, sector beta 0.54, industry beta -0.67; the factor model explains 7% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Ironwood Pharmaceuticals Inc. (IRWD) | 76.7 | A- | -66.6% |
| Viatris Inc. (VTRS) | 63.8 | B- | -13.1% |
| Teva Pharmaceutical Industries Ltd. ADR (TEVA) | 63.5 | B- | -29.4% |
| Haleon plc ADR (HLN) | 60.7 | B- | +4.3% |
| Zoetis Inc. (ZTS) | 51.2 | C | -2.7% |
United Therapeutics Corp. financial statements · Healthcare sector ranking · Drug Manufacturers - Specialty & Generic industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.